Radiation, immunotherapy, and chemotherapy before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with stage II, IIIA, or IIIB non-small cell lung cancer that can be surgically removed
- Cancer has not been treated with any prior chemotherapy, radiation, or immunotherapy
- Lungs are strong enough to handle surgical removal of part of your lung, as confirmed by your surgeon
- Blood counts and organ function (liver, kidneys, bone marrow) are adequate
- No genetic mutations (EGFR or ALK) in your cancer cells that would require different treatment
- Willing to use contraception during treatment and for 6 months after, if of childbearing age
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.